Investigational drug · Phase 2
BAY 3401016
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alport Syndrome.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BAY 3401016"
First trial start
2025
Nov 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAY 3401016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alport Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BAY 3401016" as an intervention, largest first.
- A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeActive, not recruiting
BayerBayer (BAYRY)
NCT07211685 · 60 participants (planned) · Start Nov 19, 2025 · Primary completion Nov 29, 2027
Drug: BAY 3401016 · For: Alport Syndrome
Sites: Birmingham, Alabama; Miami, Florida; Chubbuck, Idaho · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alport Syndrome
- R3R01Phase 22 trials
River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.